BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21142808)

  • 21. Biomarker targets and novel therapeutics.
    Clouser M; Hess LM; Chambers SK
    Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging targeted treatments for malignant glioma.
    Mulholland PJ; Thirlwell C; Brock CS; Newlands ES
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):845-54. PubMed ID: 16262566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA; Krauer K
    J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
    Ravandi F; Talpaz M; Estrov Z
    Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?
    Efficace F; Novik A; Vignetti M; Mandelli F; Cleeland CS
    Haematologica; 2007 Dec; 92(12):1596-8. PubMed ID: 18055981
    [No Abstract]   [Full Text] [Related]  

  • 26. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epothilone D (Kosan/Roche).
    Kolman A
    Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging targets for hematological malignancies.
    Cilloni D; Frassoni F; Saglio G
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
    Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
    Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates as targeted cancer therapeutics.
    Sun Y; Yu F; Sun BW
    Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug resistance in hematologic malignancies.
    Dalton W
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
    [No Abstract]   [Full Text] [Related]  

  • 34. Toward an effective targeted chemotherapy for multiple myeloma.
    Polson AG; Sliwkowski MX
    Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-drug conjugates in hematologic malignancies.
    Leslie LA; Younes A
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TLK-286.
    Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
    IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
    Robak T; Robak E
    Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of hematological malignancies during pregnancy.
    Rizack T; Mega A; Legare R; Castillo J
    Am J Hematol; 2009 Dec; 84(12):830-41. PubMed ID: 19844988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody Drug Conjugates for Cancer Therapy.
    Polakis P
    Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.